University of Pittsburgh Cancer Institute (UPCI)
Administration
UPCI Research Leaders
UPCI receives a total of $173 million in peer-reviewed research grants, and is ranked 10th in funding from the National Cancer Institute (NCI). More than 600 Institute faculty and staff members, representing over 30 disciplines, work together closely to improve the understanding of cancer and to develop new lifesaving procedures in cancer prevention, diagnosis, and treatment. UPCI research programs fall into the following categories: Clinical (oriented mainly towards cancer in humans), Basic (focused on the cellular and molecular activities of cancer), and Population Sciences (studying the effects of environmental, geographical, and behavioral effects on cancer).
| Leonard Appleman, MD, PhD: | Co-Leader, Prostate and Urologic Cancers Program |
| Athanassios Argiris, MD: | Co-Leader, Head and Neck Cancer Program; Co-Leader, Lung and Thoracic Malignancies Program |
| David Bartlett, MD: | Co-Leader, Liver Cancer Disease Site; Co-Leader, Surgical Oncology Disease Site |
| Dorothea Becker, PhD: | Co-Leader, Melanoma Program |
| Dana Bovbjerg, PhD: | Leader, Biobehavioral Medicine Program |
| Adam Brufsky, MD, PhD: | Co-Leader, Breast Cancer Disease Site |
| Gurkamal Chatta, MD: | Co-Leader, Cancer and Aging Program |
| Tao Cheng, MD: | Co-Leader, Cancer Stem Cell Program |
| Devra Lee Davis, PhD, MPH: | Director, Center for Environmental Oncology |
| Albert Donnenberg, PhD: | Co-Leader, Cancer Stem Cell Program |
| Maryann Donovan, PhD, MPH: | Scientific Director, Center for Environmental Oncology |
| Robert Edwards, MD: | Co-Leader, Gynecologic Oncology Disease Site |
| Merrill Egorin, MD: | Co-Leader, Molecular Therapeutics and Drug Discovery Program |
| Robert Ferris, MD, PhD: | Co-Leader, Cancer Immunology, Immunotherapy, and Immunoprevention Program |
| Olivera Finn, PhD: | Co-Leader, Cancer Immunology, Immunotherapy, and Immunoprevention Program |
| David Geller, MD: | Co-Leader, Liver Cancer Disease Site |
| Jennifer Grandis, MD: | Co-Leader, Head and Neck Cancer Program |
| Joel Greenberger, MD: | Co-Leader, Radiation Oncology Disease Site |
| Dwight Heron, MD: | Co-Leader, Radiation Oncology Disease Site |
| Ronald Johnson, MD: | Co-Leader, Breast Cancer Disease Site |
| Joseph Kelley, MD: | Co-Leader, Gynecologic Oncology Disease Site |
| John Kirkwood, MD: | Co-Leader, Melanoma Program |
| John Lazo, PhD: | Co-Leader, Molecular Therapeutics and Drug Discovery Program |
| Barry Lembersky, MD: | Interim Co-Leader, GI Cancer Disease Site |
| James Luketich, MD: | Co-Leader, Surgical Oncology Disease Site |
| Patrick Moore, MD, MPH: | Leader, Molecular Virology Program |
| Joel Nelson, MD: | Co-Leader, Prostate and Urologic Cancers Program |
| Hideho Okada, MD, PhD: | Co-Leader, Brain Tumor Program |
| Ian Pollack, MD: | Co-Leader, Brain Tumor Program |
| A. Kim Ritchey, MD: | Co-Leader, Pediatric Oncology Disease Site |
| Jill Siegfried, PhD: | Co-Leader, Lung and Thoracic Malignancies Program |
| Shivendra Singh, PhD: | Co-Leader, Biochemoprevention Program |
| Stephanie Studenski, MD, MPH: | Co-Leader, Cancer and Aging Program |
| Bennett Van Houten, PhD: | Leader, Molecular and Cell Biology Program |
| Zhou Wang, PhD: | Co-Leader, Prostate and Urologic Cancers Program |
| David Whitcomb, MD, PhD: | Leader, Cancer Genetics Program |
| Herbert Zeh, MD: | Co-Leader, GI Cancer Disease Site |
| Leader being recruited: | Cancer Epidemiology, Prevention and Control Program |
We subscribe to the